江苏迈威康新药研发有限公司是迈威(上海)生物科技股份有限公司旗下子公司, 2019年根据业务需要由江苏泰康生物医药有限公司的研发部分立而成,有工艺开发、质量研究、ADC药物开发、注册及研发合规、研发支持五个部门。迈威康能够完成工艺转化与放大、支持产品商业化上市的开发全流程工作,目前在研药物品种集中在单克隆抗体和抗体偶联药物(ADC)领域,预期2021年将有1个ADC品种进入临床阶段。
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows